Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04282681
Other study ID # LNE-800
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date March 16, 2020
Est. completion date February 28, 2022

Study information

Verified date August 2020
Source LivaNova
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this study is to collect accelerometer data from subjects monitored in an EMU with concurrent video EEG.


Description:

XLTCS (LNE-800) is an international multicenter prospective data collection study to gather accelerometer data. The population under the study comprises patients monitored in an Epilepsy Monitoring Unit (EMU) with concurrent video EEG and who are expected to have at least one seizure with tonic-clonic convulsive movement.

A maximum of one hundred and fifty (150) patients will be enrolled and will wear an accelerometer, and up to 6 sites may participate in this study. The total enrollment period will take approximately 2 years.

Once the accelerometer was adhered to the subject, subjects will be followed for a minimum of 2 days and a maximum of 10 days.

Subject participation will run concurrently with the EMU admission. Exit from the study occurs when the subject's stay in the EMU is completed or the subject is withdrawn or withdraws from the study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 28, 2022
Est. primary completion date August 28, 2021
Accepts healthy volunteers No
Gender All
Age group 4 Years to 99 Years
Eligibility Inclusion Criteria:

1. Four (4) years of age or older.

2. Admitted to an Epilepsy Monitoring Unit for video EEG monitoring.

3. Based on medical history, expected to have at least one seizure with tonic-clonic convulsive movement during the EMU stay as determined by the investigator.

4. Capable of understanding and willing to comply with instructions and study procedures.

5. Subject or guardian must be willing and able to complete informed consent/assent.

Exclusion Criteria:

1. Based on medical history, expected to have only non-epileptic events during the EMU stay as determined by the investigator.

2. Based on medical history, known to have only absence seizures.

3. Medical or psychiatric condition that in the investigator's judgment would prevent the subject's successful completion of the study.

4. Participants with known hypersensitivity or skin sensitivity conditions that will preclude attachment of the accelerometer.

5. Participants who are also taking part in another clinical trial that could confound the results of the study; these patients can be included into the study only if LivaNova has provided written approval.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Accelerometer Live-Streaming Tool
The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.

Locations

Country Name City State
Belgium Universitair Ziekenhuis Gent Ghent

Sponsors (1)

Lead Sponsor Collaborator
LivaNova

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate accelerometer data and tonic-clonic seizure data The study will evaluate accelerometer data and tonic-clonic seizure data that was collected during the patients' EMU admission. The sample size is not based on a statistical power calculation, thus no primary endpoint is defined in the clinical investigation plan. 1.5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04770337 - Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy N/A
Terminated NCT03831802 - Embrace and Quality of Life N/A
Completed NCT01439438 - Topiramate Bioequivalence Study Brazil - Fast Phase 1
Completed NCT00150787 - Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy. Phase 3
Completed NCT00231556 - A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy Phase 3
Completed NCT03446664 - Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study N/A
Completed NCT00104416 - Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures Phase 3
Completed NCT00043901 - Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug Phase 4
Completed NCT00150813 - Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. Phase 3